IDIBAPS, Institut d'Investigacions Biomèdiques August Pi i Sunyer

Resultats de l'any: 2010 2009 2008 2007

Factor d'impacte: mitjana: 8.22, total: 747.63

Articles de l'any 2008

Original

• Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic Leukemia

  Enjuanes A, Benavente Y, Bosch F, Martin-Guerrero I, Colomer D, Perez-Alvarez S, Reina O, Ardanaz MT, Jares P, Garcia-Orad A, Pujana MA, Montserrat E, DeSanjose S, Campo E
  CANCER RES . 2008; 68: 10178-10186. IF: 7.672

• Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

  Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, Miguel JS, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blade J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, VonLilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA
  LEUKEMIA. 2008; 22: 414-423. IF: 6.924

• BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells

  Perez-Galan P, Roue G, Lopez-Guerra M, Nguyen M, Villamor N, Montserrat E, Shore GC, Campo E, Colomer D
  LEUKEMIA. 2008; 22: 1712-1720. IF: 6.924

• Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

  San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Blade J, Boccadoro M, Cavenagh JD, Neuwirth R, Boral AL, Esseltine DL, Anderson KC
  LEUKEMIA. 2008; 22: 842-849. IF: 6.924

• Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

  Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Muller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM
  LEUKEMIA. 2008; 22: 1200-1206. IF: 6.924

• Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradication

  Bosch F, Ferrer A, Villamor N, Gonzalez M, Briones J, Gonzalez-Barca E, Abella E, Gardella S, Escoda L, Perez-Ceballos E, Asensi A, Sayas MJ, Font L, Altes A, Muntanola A, Bertazzoni P, Rozman M, Aymerich M, Gine E, Montserrat E
  CLIN CANCER RES. 2008; 14: 155-161. IF: 6.25

• Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling

  Roue G, Lopez-Guerra M, Milpied P, Perez-Galan P, Villamor N, Montserrat E, Campo E, Colomer D
  CLIN CANCER RES . 2008; 14: 6907-6915. IF: 6.25

• Stromal Gene Signatures in Large-B-Cell Lymphomas

  Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM
  NEW ENGL J MED . 2008; 359: 2313-2323. IF: 52.589

• Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells

  Lopez-Guerra M, Trigueros-Motos L, Molina-Arcas M, Villamor N, Casado FJ, Montserrat E, Campo E, Colomer D, Pastor-Anglada M
  HAEMATOL-HEMATOL J. 2008; 93: 1843-1851. IF: 5.516

• High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma

  Montoto S, Moreno C, Domingo-Domenech E, Estany C, Oriol A, Altes A, Besalduch J, Pedro C, Gardelia S, Escoda L, Asensio A, Vivancos P, Galan P, DeSevilla AF, Ribera JM, Briones J, Colomer D, Campo E, Montserrat E, Lopez-Guillermo A
  HAEMATOL-HEMATOL J. 2008; 93: 207-214. IF: 5.516

• Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma

  Salaverria I, Zettl A, Bea S, Hartmann EM, Dave SS, Wright GW, Boerma EJ, Kluin PM, Ott G, Chan WC, Weisenburger DD, Lopez-Guillermo A, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Jaffe ES, Staudt LM, Mueller-Hermelink HK, Campo E, Rosenwald A
  HAEMATOL-HEMATOL J. 2008; 93: 1327-1334. IF: 5.516

• Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment

  Gine E, Crespo M, Muntanola A, Calpe E, Baptista MJ, Villamor N, Montserrat E, Bosch F
  HAEMATOL-HEMATOL J. 2008; 93: 75-82. IF: 5.516

• Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia

  Fernandez V, Jares P, Salaverria I, Gine E, Bea S, Aymerich M, Colomer D, Villamor N, Bosch F, Montserrat E, Campo E
  HAEMATOL-HEMATOL J. 2008; 93: 132-136. IF: 5.516

• Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

  Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, DeLaRubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, DeArriba F, Oriol A, Carrera D, Garcia-Larana J, Garcia-Sanz R, Blade J, Prosper F, Mateo G, Esseltine DL, DeVelde HV, Miguel JFS
  HAEMATOL-HEMATOL J. 2008; 93: 560-565. IF: 5.516

• Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors of outcomes for adults transplanted in first complete remission

  Fouillard L, Labopin M, Gratwohl A, Gluckman E, Frassoni F, Beelen DW, Willemze R, Montserrat E, Blaise D, Atienza AI, Sierra J, Santos M, Gorin NC, Rocha V
  HAEMATOL-HEMATOL J. 2008; 93: 834-841. IF: 5.516

• Central nervous system involvement in mantle cell lymphoma

  Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutierrez G, Mercadal S, Campo E, Rozman C, Lopez-Guillermo A, Montserrat E
  ANN ONCOL. 2008; 19: 135-141. IF: 4.875

• Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma

  Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, Camos M, Colomo L, Espinosa I, Martinez S, Ribera JM, Martino R, Gutierrez-Garcia G, Montserrat E, Lopez-Guillermo A
  ANN ONCOL. 2008; 19: 958-963. IF: 4.875

• High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma - Comparison of results in human immunodeficiency virus-infected and noninfected patients

  Oriol A, Ribera JM, Bergua J, Mesa EG, Grande C, Esteve J, Brunet S, Moreno MJ, Escoda L, Hernandez-Rivas JM, Hoelzer D
  CANCER. 2008; 113: 117-125. IF: 4.632

• Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

  Sonneveld P, Hajek R, Nagler A, Spencer A, Blade J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ
  CANCER. 2008; 112: 1529-1537. IF: 4.632

• Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

  Lonial S, Richardson PG, Miguel JS, Sonneveld P, Schuster MW, Blade J, Cavenagh J, Rajkumar SV, Jakubowiak AJ, Esseltine DL, Anderson KC, Harousseau JL
  BRIT J HAEMATOL. 2008; 143: 222-229. IF: 4.49

• Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas

  Salaverria I, Bea S, Lopez-Guillermo A, Lespinet V, Pinyol M, Burkhardt B, Lamant L, Zettl A, Horsman D, Gascoyne R, Ott G, Siebert R, Delsol G, Campo E
  BRIT J HAEMATOL. 2008; 140: 516-526. IF: 4.49

• The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

  Niesvizky R, Richardson PG, Rajkumar SV, Coleman M, Rosinol L, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Boral AL, Esseltine DL, Anderson KC, Blade J
  BRIT J HAEMATOL. 2008; 143: 46-53. IF: 4.49

• Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial

  Ribera JM, Oriol A, Morgades M, Gonzalez-Barca E, Miralles P, Lopez-Guillermo A, Gardella S, Abella E, Garci M
  BRIT J HAEMATOL. 2008; 140: 411-419. IF: 4.49

• Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: Incidence, risk factors, and response to treatment

  Gaya A, Urbano-Ispizua A, Fernandez-Aviles F, Salamero O, Roncero JM, Rovira M, Martinez C, Talarn C, Granell M, Carreras E, Montserrat E
  BIOL BLOOD MARROW TR. 2008; 14: 880-887. IF: 3.797

• Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia

  Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Jose-Eneriz ES, Garate L, Cordeu L, Cervantes F, Prosper F, Heiniger A, Torres A
  LEUKEMIA RES. 2008; 32: 487-490. IF: 2.561

• Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis

  Alvarez-Larran A, Arellano-Rodrigo E, Reverter JC, Domingo A, Villamor N, Colomer D, Cervantes F
  ANN HEMATOL. 2008; 87: 269-276. IF: 2.342

• Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents

  Cibeira MT, Rozman M, Segarra M, Lozano E, Rosinol L, Cid MC, Filella X, Blade J
  CYTOKINE. 2008; 41: 244-253. IF: 2.169

• Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis

  DeLarrea CF, Cibeira MT, Rovira M, Rosinol L, Esteve J, Blade J
  EUR J HAEMATOL. 2008; 80: 182-184. IF: 2.163

• Short Communication Natural Killer Cells and Expression of KIR Receptors in Chronic HIV Type 1-Infected Patients after Different Strategies of Structured Therapy Interruption

  Mestre G, Garcia F, Martinez E, Milinkovic A, Leon A, Mora B, Argelich R, Lozano JM, Pena J, Gatell JM, Plana M
  AIDS RES HUM RETROV . 2008; 24: 1485-1495. IF: 2.022

• Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

  Lahuerta JJ, Mateos MV, Martinez-Lopez J, Rosinol L, Sureda A, DeLaRubia J, Garcia-Larana J, Martinez-Martinez R, Hernandez-Garcia MT, Carrera D, Besalduch J, DeArriba F, Ribera JM, Escoda L, Hernandez-Ruiz B, Garcia-Frade J, Rivas-Gonzalez C, Alegre A, Blade J, SanMiguel JF
  J CLIN ONCOL . 2008; 26: 5775-5782. IF: 15.484

• Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue

  Hartmann E, Fernandez V, Moreno V, Valls J, Hernandez L, Bosch F, Abrisqueta P, Klapper W, Dreyling M, Hoster E, Muller-Hermelink HK, Ott G, Rosenwald A, Campo E
  J CLIN ONCOL. 2008; 26: 4966-4972. IF: 15.484

• Primary cutaneous small/medium CD4(+) T-cell lymphomas: A heterogeneous group of tumors with different clinicopathologic features and outcome

  Garcia-Herrera A, Colomo L, Camos M, Carreras J, Balague O, Martinez A, Lopez-Guillermo A, Estrach T, Campo E
  J CLIN ONCOL. 2008; 26: 3364-3371. IF: 15.484

• Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy

  Mateo G, Montalban MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutierrez N, Rosinol L, Montejano L, Blade J, Martinez R, DeLaRubia J, Diaz-Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, DeArriba F, Palomera L, Terol MJ, Orfao A, Miguel JSFS
  J CLIN ONCOL . 2008; 26: 2737-2744. IF: 15.484

• Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

  Rajkumar SV, Rosinol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, Olesnyckyj M, Yu Z, Knight R, Zeldis JB, Blade J
  J CLIN ONCOL. 2008; 26: 2171-2177. IF: 15.484

• Aprospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

  Rosinol L, Perez-Simon JA, Sureda A, DeLaRubia J, DeArriba F, Lahuerta JJ, Gonzalez JD, Diaz-Mediavilla J, Hernandez B, Garcia-Frade J, Carrera D, Leon A, Hernandez M, Abellan PF, Bergua JM, Miguel JS, Blade J
  BLOOD. 2008; 112: 3591-3593. IF: 10.896

• MicroRNA expression profiling in classic Hodgkin lymphoma

  Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons A, Balague O, Gel B, Abrisqueta P, Lopez-Guillermo A, Artells R, Montserrat E, Monzo M
  BLOOD. 2008; 111: 2825-2832. IF: 10.896

• Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

  Sanz MA, Montesinos P, Vellenga E, Rayon C, DeLaSerna J, Parody R, Bergua JM, Leon A, Negri S, Gonzalez M, Rivas C, Esteve J, Milone G, Gonzalez JD, Amutio E, Brunet S, Garcia-Larana J, Colomer D, Calasanz MJ, Chillon C, Barragan E, Bolufer P, Lowenberg B
  BLOOD. 2008; 112: 3130-3134. IF: 10.896

• Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis

  Hasan SK, Mays AN, Ottone T, Ledda A, LaNasa G, Cattaneo C, Borlenghi E, Melillo L, Montefusco E, Cervera J, Stephen C, Satchi G, Lennard A, Libura M, Byl JAW, Osheroff N, Amadori S, Felix CA, Voso MT, Sperr WR, Esteve J, Sanz MA, Grimwade D, Lo-Coco F
  BLOOD. 2008; 112: 3383-3390. IF: 10.896

• Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

  Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, Mccarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT
  BLOOD. 2008; 112: 3500-3507. IF: 10.896

• The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases

  Kiladjian JJ, Cervantes F, Leebeek FWG, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Murad SD, Raffa S, Janssen HLA, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC
  BLOOD. 2008; 111: 4922-4929. IF: 10.896

• Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

  Ludwig H, Durie BGM, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopouios M, Shimizu K, Miguel JS, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J
  BLOOD. 2008; 111: 4039-4047. IF: 10.896

• Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

  DeLaSerna J, Montesinos P, Vellenga E, Rayon C, Parody R, Leon A, Esteve J, Bergua JM, Milone G, Deben G, Rivas C, Gonzalez M, Tormo M, Diaz-Mediavilla J, Gonzalez JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA
  BLOOD. 2008; 111: 3395-3402. IF: 10.896

• Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

  Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, Sureda A, Montejano L, Gutierrez NC, DeCoca AG, Heras ND, Mateos MV, Lopez-Berges MC, Garcia-Boyero R, Galende J, Hernandez J, Palomera L, Carrera D, Martinez R, DeLaRubia J, Martin A, Blade J, Lahuerta JJ, Orfao A, Miguel JFS
  BLOOD. 2008; 112: 4017-4023. IF: 10.896

• Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of HLA-identical sibling allogeneic stem cell transplantation

  Granell M, Urbano-Ispizua A, Pons A, Arostegui JI, Gel B, Navarro A, Jansa S, Artells R, Gaya A, Talarn C, Fernandez-Avilles F, Martinez C, Rovira M, Carreras E, Rozman C, Juan M, Yague J, Montserrat E, Monzo M
  BLOOD. 2008; 112: 4337-4342. IF: 10.896

Revisió

• Pathogenesis and treatment of renal failure in multiple myeloma

  Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H
  LEUKEMIA. 2008; 22: 1485-1493. IF: 6.924

• Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders

  Cervantes F, Passamonti F, Barosi G
  LEUKEMIA. 2008; 22: 905-914. IF: 6.924

• Pathogenesis and progression of monoclonal gammopathy of undetermined significance

  Blade J, Rosinol L, Cibeira MT, DeLarrea CF
  LEUKEMIA. 2008; 22: 1651-1657. IF: 6.924

• New prognostic markers in chronic lymphocytic leukemia

  Moreno C, Montserrat E
  BLOOD REV. 2008; 22: 211-219. IF: 5.922

• Advances in therapy of multiple myeloma

  Blade J, Rosinol L
  CURR OPIN ONCOL . 2008; 20: 697-704. IF: 3.692

• Thalidomide for treatment of multiple myeloma: 10 years later

  Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F, Moreau P, Waage A, Spencer A, Ludwig H, Boccadoro M, Harousseau JL
  BLOOD. 2008; 111: 3968-3977. IF: 10.896

• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

  Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ
  BLOOD. 2008; 111: 5446-5456. IF: 10.896

Editorials

• Further progress in CLL therapy

  Montserrat E
  BLOOD . 2008; 112: 924-925. IF: 10.896

• SMM: toward better predictors of progression

  Blade J, Rosinol L
  BLOOD. 2008; 111: 479-480. IF: 10.896

• Chronic myeloid leukemia 2008

  Cervantes F
  MED CLIN-BARCELONA . 2008; 131: 658-659. IF: 1.337

Tornar